Restylane Family: Hyaluronic Acid Filler Options and Applications

Restylane Product Line Overview

Restylane, manufactured by Galderma, represents one of the earliest FDA-approved hyaluronic acid dermal fillers and remains a cornerstone of aesthetic injectable practice. The Restylane family consists of multiple formulations engineered for specific anatomical applications and longevity profiles. Current product offerings include Restylane Refyne, Restylane Defyne, Restylane Contour, and Restylane Lyft, each containing non-animal origin hyaluronic acid cross-linked with biphenyl-4,4'-dicarboxaldehyde. Unlike earlier Restylane formulations using NASHA (non-animal stabilized hyaluronic acid) technology, current products utilize Galderma's proprietary cross-linking technology optimizing both clinical efficacy and durability. All Restylane products are supplied in 0.5 mL or 1.0 mL pre-filled syringes with 30-gauge needles included.

Restylane Refyne: Dynamic Expression Lines

Restylane Refyne, approved by the FDA in 2016, was specifically designed for treatment of dynamic expression wrinkles including nasolabial folds, perioral lines, and marionette lines. The formulation contains 20 mg/mL of hyaluronic acid with optimized cross-linking to provide moderate lift while preserving natural facial expression patterns. Clinical trials demonstrated that Refyne-treated nasolabial folds achieved greater than 50% improvement in the Merz scale at day 14 in 78% of treated patients, with sustained improvement evident at twelve months. The product's lower stiffness (compared to Defyne) allows it to flex with facial muscle contraction, preventing the overfilled appearance sometimes associated with stiffer fillers in highly mobile zones.

Refyne injection occurs at the mid-dermal depth (1.5-2.5 mm) using linear threading or cross-hatching techniques. Nasolabial fold treatment typically requires 0.5-1.0 mL per side; marionette line treatment 0.3-0.5 mL per side. The product integrates smoothly into facial architecture with minimal palpable firmness. Post-injection edema typically peaks at 48 hours and resolves within 5-7 days, allowing preliminary aesthetic assessment by day 7-10.

Restylane Defyne: Moderate to Deep Wrinkles

Restylane Defyne, also FDA-approved in 2016, offers greater gel stiffness and lifting capacity compared to Refyne, making it suitable for deeper wrinkles and areas requiring substantial volume correction. Defyne contains 20 mg/mL of hyaluronic acid with cross-linking optimization providing improved resistance to compression forces. Clinical efficacy studies show that 82% of Defyne-treated nasolabial folds achieved greater than one-grade improvement on photographic assessment scales at day 14, with results maintained in 76% of patients at twelve months. The stiffer formulation provides superior support for midface volume loss and moderate-to-deep folds requiring sustained structural integrity.

Defyne is injected at the deep dermis to subcutaneous junction (2.5-3.5 mm depth), using linear threading or fanning techniques. Treatment of significant nasolabial folds typically requires 0.75-1.25 mL per side; marionette lines 0.5-0.75 mL per side. The formulation's increased firmness requires gentle technique to prevent product migration and asymmetry. Post-injection edema persists slightly longer than Refyne, typically resolving by day 10-14.

Restylane Contour: Midface Volume and Cheek Augmentation

Restylane Contour, introduced in 2019, targets the large anatomical voids in cheek augmentation and chin enhancement. The formulation contains 20 mg/mL of hyaluronic acid with enhanced cross-linking optimized for deep tissue injection. Clinical data demonstrates that 86% of Contour-treated patients achieved significant cheekbone prominence and midface volume at six-month follow-up, with improvement maintained in 79% of patients at twelve months. The formulation's high G-prime value indicates substantial gel firmness suitable for bearing the mechanical forces generated during facial animation and mastication.

Contour injection occurs in the subcutaneous plane (4-5 mm depth) using 25-27 gauge cannulas to minimize vascular trauma. Bilateral cheek augmentation typically requires 1.0-1.5 mL total (0.5-0.75 mL per side), injected in linear tracks along the cheekbone apogee. Temporal hollowing treatment requires 0.3-0.5 mL per side injected in the subcutaneous plane. The formulation integrates well in the subcutaneous tissues without visible palpable irregularities. Post-injection edema may persist for 2-3 weeks, particularly in temporal regions; patient counseling regarding expected timeline is important for satisfaction.

Restylane Lyft: Classic Deep Volume Correction

Restylane Lyft, the thickest formulation in the Restylane family, contains hyaluronic acid combined with lidocaine for patient comfort during injection. Originally FDA-approved under the name Perlane in 2002, Lyft represents the deepest-placement option in the Restylane line. The formulation's robust cross-linking and high viscosity make it ideal for substantial volume loss in areas including the cheeks, chin, jawline, and temple. Clinical studies show that Lyft provides measurable volume restoration with 72% of patients maintaining significant aesthetic improvement at twelve months post-injection.

Lyft injection requires placement at the subcutaneous depth (4-5 mm) using cannulas to minimize bruising and tissue trauma. Volume recommendations vary by treatment area: cheek augmentation 1.0-1.5 mL per side, chin augmentation 0.75-1.25 mL, jawline definition 0.5-1.0 mL per side. The product's viscosity requires controlled pressure during injection to avoid excessive tissue distension. Post-injection edema and bruising may be more pronounced with Lyft than other Restylane formulations due to larger particle size; patients should expect 5-10 days recovery.

Injection Technique and Anatomical Considerations

Successful Restylane treatment requires matching formulation to anatomical location and injection depth. Superficial expression lines including lip lines and crow's feet are treated with Refyne at 1.5-2.0 mm depth using fine 30-gauge needles. Moderate wrinkles including nasolabial folds are treated with Refyne or Defyne at 2.0-2.5 mm depth using linear threading. Deep wrinkles including severe marionette lines are treated with Defyne at 2.5-3.5 mm depth. Cheek and midface volume loss is treated with Contour or Lyft at 4-5 mm depth using 25-27 gauge cannulas. Restylane products demonstrate excellent tissue integration and minimal foreign body reactions when injected at appropriate depths using proper sterile technique.

Longevity and Retreatment Intervals

Restylane product longevity varies by formulation and treatment location. Refyne and Defyne typically maintain clinical efficacy for 9-12 months; Contour for 12-15 months; and Lyft for 12-18 months based on clinical trial data. Individual variation in hyaluronic acid metabolism results in personal ranges of 6-24 months. Patients with accelerated metabolism and high physical activity may experience earlier resorption (6-9 months), while patients with lower metabolism may maintain results 18-24 months. Scheduled touch-up treatments at six-month intervals maintain consistent results; observation-based retreatment when 25-50% volume loss is perceived allows more flexible approach.

Safety Profile and Complications

Restylane products demonstrate excellent safety with low incidence of adverse effects. Transient local effects including ecchymosis, edema, and erythema occur in 10-20% of treatments and resolve within 2-7 days. Allergic reactions are extremely rare (< 0.1%) due to non-animal origin of hyaluronic acid. Vascular occlusion, while uncommon (< 0.01%), represents the most serious potential complication requiring immediate recognition and potential hyaluronidase injection. Infection risk is minimized with proper aseptic technique and post-treatment care. Superficial nodules occasionally develop with Lyft injections in mobile facial regions; these typically respond to massage, intralesional steroid injection, or limited hyaluronidase application.

Combination Strategies with Restylane

Restylane products integrate effectively with botulinum toxin for comprehensive facial rejuvenation. Patients with both dynamic expression wrinkles (crow's feet, glabellar lines) and volume loss benefit from simultaneous botulinum toxin treatment and Restylane injection. The two treatments address complementary mechanisms: botulinum toxin relaxes muscles to prevent wrinkling, while Restylane restores volume and smooths existing static wrinkles. Treatment timing should allow botulinum toxin equilibration (7-14 days) before filler injection to prevent interaction effects. Restylane also combines well with laser resurfacing and microneedling; filler should be deferred 2-4 weeks after aggressive laser treatment to allow inflammatory phase resolution.

References